243 related articles for article (PubMed ID: 35227458)
1. Investigating 5-Level EQ-5D (EQ-5D-5L) Values Based on Preferences of Patients With Heart Disease.
Gandhi M; Tan RS; Lim SL; Rand K; Lam CSP; Luo N; Cheung YB
Value Health; 2022 Mar; 25(3):451-460. PubMed ID: 35227458
[TBL] [Abstract][Full Text] [Related]
2. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
[TBL] [Abstract][Full Text] [Related]
3. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
[TBL] [Abstract][Full Text] [Related]
4. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
[TBL] [Abstract][Full Text] [Related]
5. The EQ-5D-5L Valuation Study in Egypt.
Al Shabasy S; Abbassi M; Finch A; Roudijk B; Baines D; Farid S
Pharmacoeconomics; 2022 Apr; 40(4):433-447. PubMed ID: 34786590
[TBL] [Abstract][Full Text] [Related]
6. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada.
Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA;
Med Care; 2016 Jan; 54(1):98-105. PubMed ID: 26492214
[TBL] [Abstract][Full Text] [Related]
7. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
[TBL] [Abstract][Full Text] [Related]
8. Estimating an EQ-5D-5L Value Set for China.
Luo N; Liu G; Li M; Guan H; Jin X; Rand-Hendriksen K
Value Health; 2017 Apr; 20(4):662-669. PubMed ID: 28408009
[TBL] [Abstract][Full Text] [Related]
9. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY
PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745
[TBL] [Abstract][Full Text] [Related]
10. EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery.
Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N
Patient; 2019 Aug; 12(4):383-392. PubMed ID: 30607809
[TBL] [Abstract][Full Text] [Related]
11. Valuation of EQ-5D-5L health states: a comparison of seven Asian populations.
Wang P; Liu GG; Jo MW; Purba FD; Yang Z; Gandhi M; Pattanaphesaj J; Ahn J; Wong EL; Shafie AA; Busschbach JJ; Luo N
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):445-451. PubMed ID: 30523723
[No Abstract] [Full Text] [Related]
12. Less Is More: Cross-Validation Testing of Simplified Nonlinear Regression Model Specifications for EQ-5D-5L Health State Values.
Rand-Hendriksen K; Ramos-Goñi JM; Augestad LA; Luo N
Value Health; 2017; 20(7):945-952. PubMed ID: 28712624
[TBL] [Abstract][Full Text] [Related]
13. Valuing Health State: An EQ-5D-5L Value Set for Ethiopians.
Welie AG; Gebretekle GB; Stolk E; Mukuria C; Krahn MD; Enquoselassie F; Fenta TG
Value Health Reg Issues; 2020 Sep; 22():7-14. PubMed ID: 31683254
[TBL] [Abstract][Full Text] [Related]
14. Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis.
Yang F; Wong CKH; Luo N; Piercy J; Moon R; Jackson J
Eur J Health Econ; 2019 Nov; 20(8):1195-1206. PubMed ID: 31338698
[TBL] [Abstract][Full Text] [Related]
15. German Value Set for the EQ-5D-5L.
Ludwig K; Graf von der Schulenburg JM; Greiner W
Pharmacoeconomics; 2018 Jun; 36(6):663-674. PubMed ID: 29460066
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD).
Yang F; Lau T; Lee E; Vathsala A; Chia KS; Luo N
Eur J Health Econ; 2015 Dec; 16(9):1019-26. PubMed ID: 25519850
[TBL] [Abstract][Full Text] [Related]
17. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
Golicki D; Jakubczyk M; Graczyk K; Niewada M
Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
[TBL] [Abstract][Full Text] [Related]
18. Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set.
Jyani G; Sharma A; Prinja S; Kar SS; Trivedi M; Patro BK; Goyal A; Purba FD; Finch AP; Rajsekar K; Raman S; Stolk E; Kaur M
Value Health; 2022 Jul; 25(7):1218-1226. PubMed ID: 35779943
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
[TBL] [Abstract][Full Text] [Related]
20. Valuation of the EQ-5D-5L in Taiwan.
Lin HW; Li CI; Lin FJ; Chang JY; Gau CS; Luo N; Pickard AS; Ramos Goñi JM; Tang CH; Hsu CN
PLoS One; 2018; 13(12):e0209344. PubMed ID: 30586400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
